Table 1 SPR kinetic affinities
From: Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
Clone | Mutation | TRBC1 | TRBC2 | Tm (°C) | ||||
|---|---|---|---|---|---|---|---|---|
ka (1/M) | kd (1/s) | KD (M) | ka (1/M) | kd (1/s) | KD (M) | |||
Jovi-1 | N/A | 3.57E + 05 | 5.73E-04 | 1.603E-09 | 1.19E + 06 | 1.21E + 00 | 1.02E-06 | N/A |
HuJovi-1 | N/A | 2.38E + 05 | 6.18E-04 | 2.57E-09 | 6.32E + 05 | 1.29E + 00 | 1.29E-05 | 70.7 ( ± 0.1) |
HuJovi-1 scFv-Fc | N/A | 4.04E + 05 | 0.002996 | 7.51E-09 | N/A | N/A | N/A | 72.2 ( ± 0.0) |
Mut1 | VH T28K | 1.50E + 05 | 0.001003 | 6.69E-09 | 7.82E + 04 | 0.5853 | 7.48E-06 | 70.7 ( ± 0.2) |
Mut2 | VH T28K, Y32F | 1.78E + 05 | 0.06892 | 3.87E-07 | 1.25E + 05 | 0.1248 | 9.99E-07 | 71.7 ( ± 0.1) |
Mut3 (KFN) | VH T28K, Y32F, A96N | 8.58E + 04 | 0.155 | 1.96E-06 | 8.30E + 04 | 0.0386 | 4.79E-07 | 74.3 ( ± 0.1) |
KFN scFv-Fc | VH T28K, Y32F, A96N | N/A | N/A | N/A | 1.01E + 05 | 0.09947 | 1.17E-06 | 77.1 ( ± 0.1) |
Mut4 (RFN) | VH T28R, Y32F, A96N | 8.68E + 04 | 0.1253 | 1.44E-06 | 7.76E + 04 | 0.045 | 5.815E-07 | 73.8 ( ± 0.1) |
Mut5 | VH Y32F | 1.07E + 05 | 0.04574 | 4.26E-07 | N/A | N/A | N/A | - |
Mut6 | VH A96N | 1.43E + 05 | 0.001968 | 1.38E-08 | 5129 | 0.001943 | 3.788E-07 | - |
Mut7 | VH T28K, A96N | 1.43E + 05 | 0.005239 | 3.65E-08 | 4.20E + 05 | 0.1661 | 3.952E-07 | - |
Anti HEL | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 70.7 ( ± 0.2) |
